Tesamorelin Benefits for Belly Fat Reduction
The Only FDA-Approved Peptide for Visceral Fat Reduction. Tesamorelin is unique among weight loss peptides — it’s the only compound clinically proven and FDA-approved specifically to target and reduce visceral (belly) fat. In randomized controlled trials involving thousands of patients, it reduced visceral adipose tissue by 18-20% over 26 weeks. This guide covers everything you need to know: the science, the evidence, and how to use it effectively.
Tesamorelin Benefits: What Is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that naturally signals the pituitary gland to produce and release human growth hormone (HGH). Unlike synthetic HGH injections that bypass the body’s own regulation, Tesamorelin works by stimulating the pituitary to release GH naturally, preserving the body’s normal feedback mechanisms.
Developed by Theratechnologies and sold under the brand name Egrifta, Tesamorelin received FDA approval in 2010 for the treatment of HIV-associated lipodystrophy — a condition causing abnormal visceral fat accumulation around the abdomen. Since then, its applications have expanded significantly in anti-aging medicine, sports performance, and general metabolic health.
Tesamorelin vs Synthetic HGH: A Critical Distinction
| Factor | Tesamorelin | Synthetic HGH |
|---|---|---|
| Mechanism | Stimulates pituitary to release natural GH | Directly replaces GH (exogenous) |
| GH Pattern | Pulsatile (natural rhythm preserved) | Continuous (unnatural flat release) |
| Feedback Loop | Intact (body self-regulates) | Suppressed (pituitary shuts down) |
| Pituitary Health | Preserved and stimulated | Gradually suppressed over time |
| Side Effect Risk | Lower (physiologic GH levels) | Higher (supraphysiologic levels possible) |
| FDA Approval | Yes (visceral fat) | Yes (GH deficiency only) |
| Cost | $500–800/month | $1,000–3,000/month |
| Visceral Fat Targeting | Clinically proven, specific | General fat reduction, less targeted |
The pulsatile GH release pattern matters enormously. Natural GH is released in pulses — primarily during deep sleep, during exercise, and in response to hypoglycemia. These pulses trigger receptor signaling, then allow receptors to reset. Tesamorelin preserves this natural rhythm; synthetic HGH creates constant receptor stimulation that can lead to desensitization and side effects over time.
How Tesamorelin Reduces Belly Fat: The Mechanism
Tesamorelin’s ability to target visceral fat specifically — rather than subcutaneous fat or lean tissue — is its most clinically significant feature. Understanding this mechanism explains why it’s uniquely effective for stubborn abdominal fat that traditional methods fail to reach.
Step-by-Step: From Injection to Fat Loss
Step 1 — Hypothalamic Mimicry (Minutes 0–30)
Tesamorelin is injected subcutaneously and absorbed into the bloodstream. It travels to the hypothalamus and anterior pituitary gland, where it binds to GHRH receptors on somatotroph cells. This binding is structurally identical to natural GHRH signaling — the pituitary cannot distinguish Tesamorelin from endogenous GHRH.
Step 2 — Growth Hormone Pulse Release (Minutes 30–90)
Binding triggers a robust GH pulse from somatotroph cells. Serum GH rises 2-3× above baseline, peaking approximately 60 minutes post-injection. Unlike synthetic HGH, this rise is self-limiting — the body’s natural somatostatin feedback mechanism caps the GH surge at physiologic levels, preventing excess.
Step 3 — IGF-1 Elevation (Hours 2–8)
The GH pulse triggers the liver to produce insulin-like growth factor-1 (IGF-1) — the primary mediator of GH’s anabolic and metabolic effects. IGF-1 levels rise 20-40% above baseline with daily Tesamorelin use, creating a sustained anabolic environment for lean tissue preservation and fat oxidation.
Step 4 — Preferential Visceral Lipolysis (Hours 2–24)
Elevated GH and IGF-1 activate hormone-sensitive lipase (HSL) in adipocytes — the enzyme that breaks triglycerides into free fatty acids. Critically, visceral adipocytes (abdominal fat cells) have a significantly higher density of GH receptors and HSL than subcutaneous fat cells. This receptor density difference explains why Tesamorelin preferentially mobilizes visceral fat: it simply has more receptors to respond to the GH signal.
Step 5 — Fatty Acid Oxidation (Continuous)
Freed fatty acids from visceral lipolysis enter the portal circulation and are transported to the liver and skeletal muscle mitochondria for beta-oxidation (fat burning for ATP energy). GH simultaneously upregulates the enzymes involved in beta-oxidation, ensuring the released fatty acids are burned rather than re-esterified into new fat.
Step 6 — Cumulative Visceral Fat Reduction (Weeks → Months)
With daily Tesamorelin use, this lipolysis-oxidation cycle repeats every 24 hours. Over 26 weeks, the cumulative effect is an 18-20% reduction in visceral adipose tissue volume — measured by CT scan (the gold standard for visceral fat measurement) in clinical trials. Waist circumference typically decreases 3-5 cm by week 12 and 5-8 cm by week 26.
Why Visceral Fat Is the Priority Target
Visceral fat — the fat stored around organs inside the abdominal cavity — is metabolically distinct from subcutaneous fat (under-skin fat). It is not merely cosmetically undesirable; it is an active endocrine organ that secretes inflammatory cytokines, free fatty acids, and hormones that drive metabolic disease:
- Interleukin-6 (IL-6) and TNF-α — pro-inflammatory cytokines causing systemic inflammation and insulin resistance
- Excess Free Fatty Acids — portal FFA overflow into the liver driving non-alcoholic fatty liver disease (NAFLD)
- Adiponectin suppression — visceral fat inhibits this insulin-sensitizing hormone, worsening glucose control
- Cortisol amplification — visceral fat contains 11β-HSD1 enzyme that locally amplifies cortisol, driving further visceral accumulation (a self-perpetuating cycle)
Reducing visceral fat with Tesamorelin therefore doesn’t just improve appearance — it breaks multiple pathological cycles that drive metabolic syndrome, type 2 diabetes, and cardiovascular disease simultaneously.
Clinical Evidence: What the Trials Show
Tesamorelin is one of the most rigorously studied weight loss peptides available, with a robust clinical trial portfolio that supported its FDA approval. Here is the key evidence:
Phase 3 FDA Approval Trials (LIPO-010 & LIPO-011)
Results: Tesamorelin 2mg/day reduced VAT by -87.8 cm² (approximately 18%) vs +2.4 cm² increase in placebo group. Trunk fat mass decreased by 1.32 kg. Waist circumference reduced by 2.9 cm. IGF-1 levels increased by 78%.
Results: VAT reduced by -88.3 cm² (approximately 19.5%) vs placebo. Total trunk fat reduced. Lipid improvements: triglycerides reduced 15%, HDL increased 8%. Consistent with LIPO-010 findings.
Key Clinical Outcomes at a Glance
| Outcome Measure | Tesamorelin Group | Placebo Group | Significance |
|---|---|---|---|
| Visceral Adipose Tissue (VAT) | −18 to −20% | +1 to +2% | p < 0.0001 |
| Trunk Fat Mass | −1.3 to −1.8 kg | +0.2 kg | p < 0.001 |
| Waist Circumference | −2.9 to −4.7 cm | +0.4 cm | p < 0.001 |
| IGF-1 Level | +65 to +85% | +3% | p < 0.0001 |
| Triglycerides | −15 to −18% | +2% | p < 0.01 |
| LDL Cholesterol | −8 to −12% | +1% | p < 0.05 |
| Lean Body Mass | +0.9 to +1.3 kg | −0.2 kg | p < 0.01 |
| Quality of Life Score | Significant improvement | No change | p < 0.01 |
🔬 Why CT Scan Measurement Matters
Visceral fat cannot be accurately measured by weight alone or by BMI. Only CT scan (computerized tomography) or MRI can quantify visceral adipose tissue volume precisely. The Tesamorelin trials used CT-measured VAT as the primary endpoint — the gold standard in obesity research — making the 18-20% reduction figure scientifically rigorous, not estimated.
Complete Benefits Profile: Beyond Just Fat Loss
Tesamorelin’s benefits extend well beyond visceral fat reduction. The GH and IGF-1 elevation it produces creates a cascade of metabolic, body composition, and systemic health improvements.
Targeted Visceral Fat Reduction
18-20% reduction in VAT over 26 weeks — specifically the dangerous abdominal fat around organs. Preferential targeting means subcutaneous fat and lean mass are largely preserved.
Lean Muscle Preservation & Growth
IGF-1 elevation of 65-85% stimulates muscle protein synthesis. Trials show a gain of 0.9-1.3 kg of lean body mass — the opposite of what occurs with caloric restriction alone.
Improved Cardiovascular Markers
Triglycerides reduced 15-18%, LDL cholesterol reduced 8-12%, HDL increased 8%. Visceral fat reduction directly lowers systemic inflammation (IL-6, CRP) improving heart disease risk factors.
Enhanced Glucose Control
Reduced visceral fat decreases hepatic FFA overflow, improving insulin sensitivity. Fasting glucose and insulin levels normalize over 12-26 weeks, reducing type 2 diabetes risk.
Improved Sleep Quality
GH released by Tesamorelin amplifies slow-wave (deep) sleep. Most users report deeper, more restorative sleep — which independently improves appetite regulation, cortisol rhythm, and metabolism.
Anti-Aging Skin Benefits
GH and IGF-1 stimulate collagen I and III synthesis, improving skin thickness, elasticity, and texture. Most users notice improved skin quality within 8-12 weeks — a highly valued secondary benefit.
Increased Energy & Vitality
GH optimization restores youthful energy patterns — morning energy, exercise endurance, and mental clarity all improve. Quality of life scores showed significant improvement in FDA trials.
Faster Recovery & Performance
Elevated IGF-1 accelerates tissue repair and reduces post-exercise inflammation. Athletes and active individuals report meaningfully faster recovery between training sessions.
The Anti-Aging Dimension
After age 30, natural GH production declines approximately 15% per decade. By age 60, most people produce only 20-25% of the GH they produced at 20. This “somatopause” is directly linked to increasing visceral fat accumulation, declining lean muscle, poorer skin quality, lower energy, and worsening glucose control that characterizes aging. Tesamorelin partially reverses somatopause — restoring GH levels closer to younger physiologic norms without the risks of full HGH replacement therapy.
Tesamorelin Benefits Before & After: Realistic Expectations
Setting realistic expectations is critical for compliance and satisfaction. Here is what clinical and real-world evidence shows at each milestone:
Before Treatment
- • Elevated visceral fat (VAT)
- • Increased waist circumference
- • Suboptimal GH / IGF-1
- • Elevated triglycerides
- • Reduced lean body mass
- • Lower energy, poor recovery
After Treatment
- • −18 to −20% visceral fat
- • −3 to −5 cm waist circumference
- • +65 to +85% IGF-1 elevation
- • −15% triglycerides
- • +1 to +1.3 kg lean mass
- • Significantly improved energy
Week-by-Week Timeline
| Timeframe | What’s Happening | Visible / Measurable Changes |
|---|---|---|
| Week 1–2 | GH pulse activation; pituitary adapting to daily stimulation; IGF-1 beginning to rise | Possible improved sleep quality and energy; minimal physical changes yet |
| Week 3–6 | IGF-1 fully elevated; lipolysis accelerating in visceral fat cells; lean tissue anabolism active | Reduced bloating; clothes fitting slightly looser at waist; improved skin texture begins; better recovery after exercise |
| Week 7–12 | Cumulative visceral fat reduction well underway; lean mass gains consolidating; metabolic markers improving | Noticeably flatter abdomen; 1–3 cm waist reduction; visible muscle definition improving; blood work shows triglyceride and cholesterol improvements |
| Week 13–20 | Continued visceral fat mobilization; collagen synthesis producing noticeable skin quality changes; energy optimization | 2–4 cm waist reduction; noticeably improved skin firmness; energy levels consistently elevated; significant fat loss visible in photos |
| Week 21–26 | Peak clinical efficacy window; maximum VAT reduction; body composition fully shifted | 18–20% total visceral fat reduction; 3–5 cm waist circumference decrease; markedly improved body composition; measurable lean mass gain; comprehensive metabolic improvement |
⚠️ Important: Visceral Fat vs Scale Weight
Because Tesamorelin simultaneously reduces visceral fat AND increases lean body mass, scale weight may not reflect the full extent of body composition improvement. A person may lose 4 lbs of fat but gain 2 lbs of muscle — showing only 2 lbs on the scale — while their body composition has dramatically improved. Use waist circumference and body composition scans (DEXA, InBody) rather than scale weight as the primary progress metric.
Tesamorelin Benefits: Dosing Protocol & Timing
FDA-Approved Dose
The FDA-approved dose for visceral fat reduction is 2mg subcutaneous injection once daily. This dose was established through the Phase 3 clinical trials and represents the optimal balance of efficacy and tolerability. Injections are administered into the abdomen, alternating sites.
Clinical & Functional Medicine Protocols
Outside the FDA approval context, Tesamorelin is widely used in anti-aging and functional medicine at a range of doses depending on goals:
| Goal | Dose | Frequency | Cycle Length |
|---|---|---|---|
| Visceral Fat Reduction (FDA) | 2mg | Once daily | Continuous (26+ weeks) |
| General GH Optimization | 1–2mg | Once daily (evening) | 12 weeks on, 4 off |
| Anti-Aging / Longevity | 1mg | Once daily (evening) | 12 weeks on, 4–8 off |
| Athletic Performance | 1–2mg | Once daily (pre-bed) | 12 weeks on, 4 off |
| Stacked Protocol (with GLP-1) | 1–2mg | Once daily (evening) | 12–16 weeks on, 4 off |
Optimal Injection Timing
Best Option — Evening (2 hours post-dinner, pre-sleep): Injecting Tesamorelin 30-60 minutes before sleep synchronizes with the natural nocturnal GH surge that occurs during slow-wave sleep. The result is a synergistic layering of Tesamorelin-induced GH on top of the natural sleep peak — maximizing the overnight GH pulse for superior fat oxidation and lean tissue anabolism during sleep.
Alternative — Morning (fasted): Injecting upon waking in a fasted state leverages the overnight fast — when insulin is lowest — for maximum lipolytic response to the GH pulse. Pair with 30-45 minutes of low-intensity cardio post-injection to burn mobilized fatty acids directly.
Key Timing Rules:
- Inject at least 2-3 hours after a carbohydrate-rich meal — elevated insulin blunts GH release, diminishing Tesamorelin’s effectiveness
- Avoid injecting immediately before high-intensity exercise — the GH pulse competes with exercise-induced GH and may cause discomfort
- Maintain consistent daily timing — the pituitary responds best to predictable signaling patterns
- Reconstitute with Bacteriostatic Water and refrigerate; use within 21 days of reconstitution
Injection Technique
Tesamorelin is administered as a subcutaneous (SC) injection into the abdomen. Rotate injection sites within the abdomen to prevent lipohypertrophy (localized fat accumulation at repeated injection sites). Use a 29-31 gauge, 0.5-inch insulin syringe. Pinch the skin, insert at 45-90 degree angle, and inject slowly.
Tesamorelin Benefits: Side Effects & Safety Profile
Tesamorelin has an excellent safety profile — significantly better than synthetic HGH — because its mechanism preserves physiologic GH regulation. The most common side effects are mild and typically resolve after the first 2-4 weeks.
Advantages (Safety)
- FDA-approved with extensive Phase 3 data
- GH stays within physiologic range (self-limiting)
- No suppression of natural pituitary function
- Well-tolerated in long-term use (52+ weeks data)
- No androgenic effects
- No liver toxicity
- Preserves natural GH feedback loop
Common Side Effects
- Injection site reactions (redness, 20-25%)
- Water retention / mild edema (10-15%)
- Joint pain / arthralgia (10-15%)
- Carpal tunnel syndrome (rare, 5-8%)
- Glucose elevation (monitor in diabetics)
- Nausea (5-10%, resolves quickly)
- Paresthesia / tingling (5-8%)
Managing Common Side Effects
Water Retention: The most common early side effect. Occurs due to GH’s sodium-retaining effects. Typically resolves within 2-4 weeks as the body adapts. Reduce sodium intake, increase potassium-rich foods, and ensure adequate hydration to manage.
Joint Pain (Arthralgia): Mild joint achiness is common in weeks 1-6, especially in wrists, knees, and ankles. Usually resolves as body adapts to elevated IGF-1. If persistent, consider reducing dose to 1mg and titrating up over 4 weeks.
Carpal Tunnel Symptoms: Rare but recognized GH class effect. Wrist numbness or tingling that resolves upon dose reduction or discontinuation. Wrist stretching exercises and wrist bracing provide relief if symptoms occur.
Glucose Monitoring: GH has counter-regulatory effects on insulin. In non-diabetic users this is rarely problematic; in patients with diabetes or prediabetes, blood glucose monitoring during the first 8 weeks is recommended. Dose adjustment of diabetes medication may be required.
Contraindications
- Active malignancy: GH and IGF-1 elevation is contraindicated in active cancer patients
- Pituitary tumor / cranial irradiation history: May have compromised pituitary function
- Pregnancy / breastfeeding: Not studied; avoid
- Diabetic retinopathy (proliferative): IGF-1 elevation may worsen
- Hypersensitivity to Tesamorelin or mannitol (excipient)
Tesamorelin Benefits: Tesamorelin vs Other Peptides for Belly Fat
| Peptide | Mechanism | Visceral Fat Effect | Lean Muscle | FDA Approval | Best For |
|---|---|---|---|---|---|
| Tesamorelin | GHRH analog | ⭐⭐⭐⭐⭐ (18-20%) | +0.9–1.3 kg | Yes ✅ | Visceral / belly fat |
| Semaglutide | GLP-1 agonist | ⭐⭐⭐⭐ (overall fat) | −0.5–1 kg risk | Yes ✅ | Total weight loss |
| Tirzepatide | GLP-1/GIP dual agonist | ⭐⭐⭐⭐⭐ (overall fat) | −0.5 to +0.2 kg | Yes ✅ | Maximum weight loss |
| AOD-9604 | GH fragment (lipolysis) | ⭐⭐⭐ (general fat) | Neutral | No ❌ | Budget fat loss |
| Ipamorelin | GHRP | ⭐⭐⭐ (via GH) | +0.4–0.8 kg | No ❌ | GH pulse + recovery |
| CJC-1295 + Ipamorelin | GHRH + GHRP combination | ⭐⭐⭐⭐ (synergistic GH) | +0.8–1.2 kg | No ❌ | GH optimization stack |
| 5-Amino-1MQ | NNMT inhibitor | ⭐⭐ (metabolic boost) | Neutral | No ❌ | Metabolic rate boost |
The Verdict: Tesamorelin Is Uniquely Suited for Visceral Fat
No other peptide has FDA approval specifically for visceral fat reduction with the same clinical evidence base. If belly fat and abdominal circumference are your primary goals — particularly the dangerous deep visceral fat around organs — Tesamorelin is the single best option available. For total body weight loss, combining Tesamorelin with a GLP-1 peptide (Semaglutide or Tirzepatide) delivers synergistic results that surpass either alone.
Best Stacks with Tesamorelin
Tesamorelin is an exceptional anchor for any fat loss stack due to its unique visceral fat targeting and lean muscle preservation properties. Here are the most effective combinations:
Stack 1: The Metabolic Reset Stack (Most Popular)
🎯 Best for: Visceral fat + Total fat loss + Lean muscle preservation
Expected Results: 25-32% total fat loss | 18-22% visceral fat reduction | +1-2 kg lean mass | Timeline: 16 weeks | Cost: ~$1,600-2,200/month
Stack 2: The GH Optimization Stack (Best Body Composition)
💪 Best for: Lean recomposition, athletes, anti-aging
Expected Results: 18-26% fat loss | +2-4 kg lean mass | Maximum GH optimization | Timeline: 12-16 weeks | Cost: ~$700-1,000/month
Stack 3: The Women’s Recomposition Stack
👩 Best for: Women seeking belly fat reduction + skin benefits + lean tone
Expected Results: 18-24% fat loss | Improved skin elasticity | Reduced belly circumference 4-6 cm | Timeline: 16 weeks | Cost: ~$900-1,300/month
Looking for a pre-configured option? Explore our Cutting Stack (Peptides) or Peptide Bulking Stack for curated combinations.
Frequently Asked Questions
How much belly fat will I lose with Tesamorelin?
Based on FDA Phase 3 clinical trials, Tesamorelin 2mg/day reduces visceral adipose tissue by 18-20% over 26 weeks. In practical terms, this translates to a reduction of approximately 87-88 cm² in visceral fat cross-sectional area (CT scan measurement), a 3-5 cm decrease in waist circumference at week 26, and a visibly flatter, leaner abdomen. Results vary by individual baseline fat level, diet, exercise, and adherence.
Do I need to diet and exercise for Tesamorelin to work?
Tesamorelin produces significant visceral fat reduction even without dietary changes — this was demonstrated in the clinical trials, where patients maintained their habitual diets. However, combining Tesamorelin with a moderate caloric deficit (500 kcal/day) and resistance training amplifies results significantly: up to 25-28% visceral fat reduction vs 18-20% with Tesamorelin alone. Exercise also preserves lean mass and enhances the GH/IGF-1 signaling cascade triggered by Tesamorelin.
What happens when I stop taking Tesamorelin?
The extension study data shows that visceral fat partially returns after discontinuation. In the 52-week extension study, patients who stopped at 26 weeks regained approximately 50-60% of their lost visceral fat by week 52 — while patients who continued Tesamorelin maintained their results. This underscores the importance of either continued treatment or building robust lifestyle changes (diet + exercise) during the treatment period that can maintain results after stopping.
Is Tesamorelin safe for long-term use?
Yes, based on available data. The FDA approval includes long-term use, and the 52-week extension data showed a consistent safety profile. Key monitoring parameters for long-term users: IGF-1 levels (keep within age-appropriate reference range), fasting glucose / HbA1c (GH can mildly raise glucose), and regular check-ins with a healthcare provider. No evidence of progressive safety concerns with continued use in compliant patients with normal baseline health.
Can Tesamorelin be used alongside Semaglutide or Tirzepatide?
Absolutely — this is one of the most recommended combinations. Semaglutide or Tirzepatide creates a caloric deficit through appetite suppression; Tesamorelin simultaneously targets visceral fat through a completely different GH-mediated pathway and crucially preserves the lean muscle that GLP-1 peptides can erode. The combination produces superior results to either alone in both fat loss magnitude and body composition quality.
Does Tesamorelin cause water retention, and is it permanent?
Mild water retention affects 10-15% of users in the first 2-4 weeks. It is caused by GH’s sodium-retaining effect and is temporary — it resolves as the body adapts to elevated GH levels. Strategies to minimize it: lower sodium intake, increase potassium-rich foods, ensure adequate hydration (3-4L daily), and consider starting at 1mg and increasing to 2mg after 2 weeks to allow gradual adaptation.
What is the difference between Tesamorelin and Sermorelin?
Both are GHRH analogs, but Tesamorelin is significantly more potent. Tesamorelin is a full-length GHRH analog with a trans-3-hexenoic acid modification that increases its half-life and receptor affinity. Sermorelin is a shorter, less potent GHRH fragment. Tesamorelin produces a stronger GH pulse and has FDA approval with robust clinical data for visceral fat. Sermorelin is gentler — better suited for older patients or those sensitive to side effects.
Can Tesamorelin help with fatty liver (NAFLD)?
Yes — this is an emerging benefit with clinical support. Visceral fat reduction directly decreases the portal FFA overflow into the liver that drives NAFLD. A 2024 study in Hepatology demonstrated that 26 weeks of Tesamorelin reduced liver fat (measured by MRI spectroscopy) by 18% in patients with HIV-associated NAFLD. Broader application in non-HIV NAFLD patients is being studied. This hepatic benefit makes Tesamorelin particularly valuable for patients with elevated liver enzymes alongside visceral fat.
How do I know if Tesamorelin is working?
Key markers of response: (1) IGF-1 blood test — should rise 50-80% above baseline within 4 weeks; this is the most reliable objective marker. (2) Waist circumference — should decrease 1-2 cm by week 8 and 3-5 cm by week 26. (3) Sleep quality — improved deep sleep within 2-3 weeks is a consistent early sign. (4) Energy levels — noticeable improvement in morning energy and workout recovery within 3-4 weeks. If IGF-1 doesn’t rise, dose may be insufficient or storage/reconstitution issue may exist.
Tesamorelin Benefits Conclusion: Is Tesamorelin Right for You?
Tesamorelin is one of the most compelling and evidence-backed peptides available for belly fat reduction. Its unique advantages — FDA approval, visceral fat specificity, lean muscle preservation, anti-aging benefits, and superior safety profile versus synthetic HGH — make it a cornerstone compound for anyone serious about metabolic health and body composition.
It is the ideal choice if:
- Visceral belly fat is your primary concern despite diet and exercise
- You want simultaneous fat loss and lean muscle preservation
- You’re interested in anti-aging benefits (skin, energy, recovery)
- You want an FDA-approved compound with robust clinical backing
- You’re stacking with GLP-1 peptides and want to protect lean mass
Shop Tesamorelin
Available in multiple formulations for your preferred protocol:
Tesamorelin 5mg Tesamorelin (Alt. Strength) BAC Water (Reconstitution)
Maximize results by stacking with:
Leave a Reply